Cover image of PeerView Internal Medicine CME/CNE/CPE Audio Podcast
(14)
Science & Medicine
Medicine

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Updated 13 days ago

Science & Medicine
Medicine
Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

iTunes Ratings

14 Ratings
Average Ratings
6
3
1
2
2

AmaZing Material for internists

By Dr.Job - Jan 16 2010
Read more
I cannot describe how nice and neat it was to listen to this material. Basim Ayoub, MD

iTunes Ratings

14 Ratings
Average Ratings
6
3
1
2
2

AmaZing Material for internists

By Dr.Job - Jan 16 2010
Read more
I cannot describe how nice and neat it was to listen to this material. Basim Ayoub, MD
Cover image of PeerView Internal Medicine CME/CNE/CPE Audio Podcast

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Updated 13 days ago

Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Rank #1: Thomas F. Patterson, MD, FACP, FIDSA - Overcoming Barriers to Optimal Diagnosis and Treatment of Invasive Fungal Infections: Practical Guidance for the Hospital-Based Healthcare Provider

Podcast cover
Read more
Overcoming Barriers to Optimal Diagnosis and Treatment of Invasive Fungal Infections: Practical Guidance for the Hospital-Based Healthcare Provider
Sep 10 2018
26 mins
Play

Rank #2: Kimberly Halla, MSN, FNP-C - Realizing the Promise of PARP Inhibitors in Solid Tumor Therapy: Guiding Oncology Nurses on the Advances and Challenges

Podcast cover
Read more
Go online to PeerView.com/KWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView MasterClass, an expert panel of oncology nurse professionals presents the highlights of emerging science and clinical data on PARP inhibition in multiple solid tumors, assesses the role of companion diagnostic tests that identify patients with DDR mutations, as well as engage the audience in a stimulating discussion on the value of genetic testing and significance of enrollment in ongoing PARP inhibitor clinical trials. Going beyond the standard didactic lectures, our experts share their own perspectives on best practice strategies to effectively and safely use approved and emerging PARP inhibitors within the framework of challenging case scenarios. Upon completion of this activity, participants will be able to: Describe DNA-damage response (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors as a cancer therapeutic strategy, Assess the clinical role, efficacy, and safety of PARP inhibitors in multiple tumor types, including ovarian, breast, pancreatic, and prostate cancers, across different treatment settings, Counsel patients receiving PARP inhibitor therapy on strategies to prevent and/or manage treatment emergent adverse events, Provide appropriate education and guidance to patients on the safe and effective clinical use of novel PARP inhibitors, including dosing, the need for adherence to therapy, and enrollment into clinical trials.
Jun 05 2019
1 hour 8 mins
Play

Rank #3: Doreen Addrizzo-Harris, MD - Advances in the Management of Nontuberculous Mycobacterial Lung Disease (NTM-LD): Expert Insights From Dallas

Podcast cover
Read more
Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.
Jul 08 2019
28 mins
Play

Rank #4: Javed Butler, MD, MPH, MBA - New Frontiers in Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?

Podcast cover
Read more
Go online to PeerView.com/ZAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular medicine explores the new frontiers in managing heart failure and the role of SGLT2 inhibitors in optimizing care for patients with or at risk of heart failure. Upon completion of this activity, participants should be better able to: Apply current recommendations designed to minimize the risks of hospitalizations and mortality in patients being treated for heart failure, Summarize current evidence regarding the potential therapeutic role, efficacy, and safety of SGLT2 inhibitors in the heart failure setting, Identify patients with or at risk of heart failure who could potentially derive benefit from therapy with SGLT2 inhibitors.
Jun 26 2019
31 mins
Play

Rank #5: Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings

Podcast cover
Read more
Go online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and address several ongoing clinical questions from the choice of novel induction and maintenance options to minimal residual disease monitoring and the use of newer therapeutic platforms for post-transplant relapsed disease. Upon completion of this activity, participants should be better able to: Summarize evidence regarding the safety, efficacy, and current clinical role of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma, Develop personalized induction and post-ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma, Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT.
Apr 22 2019
54 mins
Play

Rank #6: John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

Podcast cover
Read more
Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.
Jul 05 2019
40 mins
Play

Rank #7: John E. Anderson, MD - Realizing Your Patient’s Potential: Embracing the Guidelines to Appropriately Individualize Care for Patients With Type 2 Diabetes

Podcast cover
Read more
Go online to PeerView.com/UQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in internal medicine offers insight on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Recognize the primary goals of treatment and key components involved in providing effective patient-centered care to individuals with T2DM, Apply recommendations offered in current evidence-based guidelines to appropriately individualize antihyperglycemic therapy for patients with T2DM.
May 06 2019
32 mins
Play

Rank #8: Stewart J. Tepper, MD, FAHS - Recognition and Management of Migraine in an Era of Expanding Options for Acute Treatment and Prevention

Podcast cover
Read more
Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.
Apr 26 2019
53 mins
Play

Rank #9: Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

Podcast cover
Read more
Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.
Jul 01 2019
17 mins
Play

Rank #10: Jonathan Corren, MD and Paul Yamauchi, MD - Advances in the Management of Allergic and Inflammatory Diseases: Highlights From Washington, DC and San Francisco

Podcast cover
Read more
Go online to PeerView.com/NCE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in allergy and dermatology discuss advances in the management of allergic and inflammatory diseases presented at the 2019 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic rhinosinusitis and nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), Discuss emerging data related to the efficacy and safety of therapies for the treatment of allergic and inflammatory diseases, Apply the latest clinical data to the treatment of patients with allergic and inflammatory disorders, such as atopic dermatitis, asthma, CRS/NP, and EoE.
Apr 29 2019
39 mins
Play

Similar Podcasts